We are a leading provider of AI-driven precision pathology software for research and diagnostics. In research, we are a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, we are a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows.
Founded in 2002, we are privately owned and operate internationally with over 750 customer accounts in more than 40 countries. Our company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.
We are a privately owned company, founded in 2002 by our Managing Director and Chief Executive Officer, Michael Grunkin, and Chief Technical Officer, Johan Doré Hansen. Both Grunkin and Hansen have a strong scientific and practical background in image analysis.
Our solutions have been featured in over 3,300 scientific publications. We are certified according to EN ISO 13485:2016, covering the design, development, manufacture, installation, and service of in vitro diagnostic pathology software.
Our company has grown into an international business with over 750 accounts in more than 40 countries. Our growing network of authorized distributors and partners support the growth of Visiopharm’s solutions on several continents including North America, Europe, and Asia.
Visiopharm Earns Acclaim from Frost & Sullivan for Transforming Anatomic Pathology. Frost & Sullivan recognizes Denmark-headquartered Visiopharm A/S with the 2019 Global Company of the Year Award. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Visiopharm was recognized by CIO Applications Magazine as CIO Applications Top 25 Machine Learning Solution Provider 2019. CIO Applications brings you the “Top 25 Machine Learning Solution Providers – 2019”. The CIO Application Magazine states: “The list features some of the most prominent machine solution providers in the industry that have excelled in their services and product portfolio in the ML space”.
Visiopharm wins Denmark’s leading business newspaper “Dagblade Børsen” Gazelle Growth Accellerator, the prestigious award “Børsen Gazelle 2017” as an identification of Denmark’s absolute growth elite.
The award is given as a recognition to achieve a continuous growth in revenue or gross profit for the last four financial years, and which has, in total, more than doubled the revenue or the gross profit in the period.
Visiopharm was promoted two times for EY Entrepreneur of the Year in 2016 and 2017. We were placed among the top three nominees for the finalist in the Life Science category in 2017.
Ernst & Young, EY Entrepreneur Of The Year™ awards recognize and celebrate unstoppable entrepreneurs in their field.
We are an exclusive distributor of Hamamatsu’s NanoZoomer whole slide scanners in the Netherlands and Denmark. Hamamatsu fuses cutting-edge hardware technology with the philosophy of intuitive interface design. As a result, the NanoZoomer series offers high productivity and user acceptance within multiple whole slide imaging application environments.
CGI is a leading provider of end-to-end digital pathology solutions for a truly digital, highly efficient workflow that encompasses all processes from sample requisition to diagnosis. With over 20 years of experience and profound domain expertise, CGI continues to improve and expand its pathology solutions, helping the public health sector in Denmark maintain its position as a world leader in pathology. CGI’s pathology solutions are used by all five regions in Denmark, as well as in pathology labs in public and private hospitals both in Denmark and abroad.
The aim of Nordic Immunohistochemical Quality Control (NordiQC) is to promote the quality of immunohistochemistry and expand its clinical use by organizing schemes for immunohistochemical staining and providing examples of good protocols, along with other information such as epitope descriptions and technical solutions. We have a close collaboration with NordiQC for the development and validation of IHC APPs.
We are a global distributor of ISENET’s Galileo CK family of TMA instruments, which provides an open architecture and creates the perfect environment for client customizations. These customizations include the use of different size blocks and other unique features, such as the ability to use 96-well plates or Eppendorf vials for Tissue Core Nucleic Acid Extractions. Additionally, the instruments offer a record of core position and donor IDs within an electronic report. This feature also allows for the export of the XML file to any commercial digital scanner (eg, Aperio, Hamamatsu), enabling the lab to continue using their preferred digital scanner and visual imaging software.
Akoya Biosciences develops innovative technologies for life science researchers, enabling spatially-resolved, quantitative tissue phenotyping at the cellular and subcellular level. The combined technologies of Phenoptics and CODEX are driving advances in next-generation tissue analysis by offering comprehensive solutions that include instrumentation, reagents, and software. Akoya Biosciences is headquartered in Menlo Park, CA.
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company, Agilent delivers insight and innovation towards improving the quality of life. Agilent’s instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions.
By seamlessly integrating our image analysis (IA) suite into Proscia’s Concentriq® image management system (IMS), we are creating a connected digital ecosystem that eliminates data silos and facilitates the incorporation of analysis results into routine research. As a result, users can make faster, more informed decisions in image-based research.
UK NEQAS aims to improve patient care by independently and not-for-profit monitoring the quality of tests and their reporting. They are dedicated to ensuring optimal quality in testing for the benefit of patients. UK NEQAS believes that test results should be comparable, safe, and clinically useful to the patient, regardless of where or when they are performed.
